Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Cardiovascular Neurology Companies

CNS Protein changes name to Amarantus

This article was originally published in Scrip

Executive Summary

CNS Protein Therapeutics, a private US biotechnology company, has changed its name to Amarantus Therapeutics and has appointed Martin Cleary CEO. The name change reflects Amarantus's new strategy to develop its first novel drug candidate, the growth factor AMRS001, for the treatment of Parkinson's disease and myocardial infarction. Mr Cleary, formerly president and CEO of vaccine company Juvaris BioTherapeutics, succeeds the company's co-founder Gerald Commissiong, who becomes chief business officer.

Table

View full table

Topics

Related Companies

Tags:
Cardiovascular Neurology Companies
Latest Headlines

Competition Forces Price Cuts, But Novo Nordisk Is Unstoppable

Metagenomi Looks For Upside To Moderna’s Exit

Executives On The Move: Senior Moves At Innovent Biologics, Actym Therapeutics And Enanta Pharmaceuticals

Japan Results Roundup: Weak Yen Provides A Boost But Some Sales Challenges Emerge

See All
UsernamePublicRestriction

Register

SC005360

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By